Ghrelin: A history of its discovery

Ghrelin in Health and Disease

Volumn , Issue , 2012, Pages 1-35

  Bowers, Cyril Y ^a   Reynolds, G A ^a   Veldhuis, Johannes D ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85024932478     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-903-7_1     Document Type: Chapter

References (89)

1. Bowers CY, Chang J, Momany F, et al. Effect of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. In: MacIntyre I, Szelke M, editors. Molecular endocrinology. Amsterdam: Elsevier/North-Holland Biomedical Press; 1977. p. 287-92.
2. Bowers CY, Momany F, Chang K, et al. Structure activity relationships of a synthetic pentapeptide that speci fi cally releases GH in vitro. Endocrinology. 1980;106:663-7.
3. Bowers CY, Reynolds GA, Chang K, et al. A study on the regulation of GH release from the pituitaries of rats, in vitro. Endocrinology. 1981;108:1071-9.
4. Momany FA, Bowers CY, Reynolds GA, et al. Design, synthesis and biological activity of peptides which release growth hormone, in vitro. Endocrinology. 1981;108:31-9.
5. Momany F, Bowers CY, Reynolds GA, et al. Conformational energy studies and in vitro activity data on active GH releasing peptides. Endocrinology. 1984;114:1531-6.
6. Bowers CY, Momany F, Reynolds GA. In vitro and in vivo activity of a small synthetic peptide with potent GH releasing activity. San Francisco, CA: The Endocrine Society. June 15-18, 1982. p. 205.
7. Bowers CY, Momany F, Reynolds GA, et al. On the In vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to speci fi cally release growth hormone. Endocrinology. 1984;114:1537-45.
8. Bowers CY, Reynolds GA, Momany F. New advances on the regulation of growth hormone (GH) secretion. Int J Neurol. 1984;18:188-205.
9. Guillemin R, Brazeau P, Bohlen P, et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218:585-7.
10. Rivier J, Spiess J, Thorner M, et al. Characterization of a growth hormone releasing factor from a human pancreatic islet tumor. Nature. 1982;300:276-8.
11. Guillemin R. Growth hormone releasing factor: a brief history of its time. In: Bercu B, Walker R, editors. Growth hormone secretagogues. New York, NY: Springer-Verlag; 1996. p. 3-8.
12. Thorner MO, Perryman RL, Cronin A, et al. Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone releasing factor. J Clin Invest. 1982;70:965-76.
13. Thorner MO, Spiess J, Vance ML, et al. Human pancreatic growth hormone-releasing factor selectively stimulated growth-hormone secretion in man. Lancet. 1983;1:24-8.
14. Frohman LA, Szabo M, Berelowitz M, et al. Partial puri fi cation and characterization of a peptide with growth hormone activity from extra-pituitary tumors in patients with acromegaly. J Clin Invest. 1980;65:43-54.
15. Bowers CY, Reynolds GA, Hong A, et al. Studies on pituitary cyclic AMP and GH levels and the release of GH in vitro. In: Bhatnager AS, editor. The anterior pituitary gland. New York, NY: Raven Press; 1983. p. 165-76.
16. Brazeau P, Ling N, Esch F, et al. Somatocrinin (growth hormone releasing factor) in vitro bioactivity, Ca ++ involvement, cAMP mediated action and additivity of effect with PGE 2. Biochem Biophys Res Commun. 1982;109:588-94.
17. Bowers CY, Veeraragavan K, Sethumadhavan K. Atypical growth hormone releasing peptides. In: Bercu B, Walker R, editors. Growth hormone II basic and clinical aspects. New York, NY: Springer-Verlag; 1994. p. 203-22.
18. Bowers CY, Sartor AO, Reynolds GA, et al. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1991;128:2027-35.
19. Badger RM, Millard WJ, McCormick GF, et al. The effect of growth hormone (GH) releasing peptide on GH secretion in perifused pituitary cells of adult male rats. Endocrinology. 1984;115:1432-8.
20. McCormick GF, Millard WJ, Badger TM, et al. Dose-response characteristics of various peptides with growth hormone releasing activity in the unanesthetized male rat. Endocrinology. 1985;117:97-105.
21. Sartor O, Bowers CY, Chang D. Parallel studies of HisDTrpAlaTrpDPheLysNH 2 and hpGRF in rat pituitary primary cell monolayer culture. Endocrinology. 1985;116:952-7.
22. Sartor O, Bowers CY, Reynolds GA, et al. Variable determining the GH response of HisDTrpAlaTrpDPheLysNH 2 (GHRP-6) in the rat. Endocrinology. 1985;117:1441-7.
23. Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984; 115:1952-7.
24. Plotsky P, Vale W. Patterns of growth hormone-releasing factor and somatostatin into the hypophyseal portal circulation of the rat. Science. 1985;230:461-3.
25. Brazeau PW, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77-9.
26. Momany FA, Bowers CY. Computer-assisted modeling of Xenobiotic growth hormone secretagogues. In: Bercu B, Walker R, editors. Growth hormone secretagogues. New York, NY: Springer-Verlag; 1996. p. 73-83.
27. Sethumadhavan K, Veeraragavan K, Bowers CY. Demonstration and characterization of the speci fi c binding of growth hormone-releasing peptide (GHRP) to rat anterior pituitary and hypothalamic membranes. Biochem Biophys Res Commun. 1991;178:31-7.
28. Bitar KG, Bowers CY, Coy DH. Effects of substance P/Bombesin antagonists on the release of growth hormone by GHRP and GHRH. Biochem Biophys Res Commun. 1991;180:156-61.
29. Veeraragavan K, Sethumadhavan K, Bowers CY. Growth hormone releasing peptide (GHRP) binding to porcine anterior pituitary and hypothalamic membranes. Life Sci. 1992;50:1149-55.
30. Smith RG, Cheng K, Schoen S, et al. A novel nonpeptidyl growth hormone secretagogue. Science. 1993;260:1640-3.
31. Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci USA. 1995;92:7001-5.
32. Patchett AA, Wyvratt MJ. The design of peptidomimetic growth hormone secretagogues. In: Smith RG, Thorner MO, editors. Human growth hormone. Totowa, NJ: Humana Press, Inc; 2000. p. 45-67.
33. Codd EE, Shi AYL, Walker RF. Bonding of a growth hormone releasing hexapeptide to speci fi c hypothalamic and pituitary sites. Neuropharmacology. 1989;28:1139-44.
34. Cheng K, Chan WWS, Barreto A, et al. The synergistic effects of HisDTrpAlaTrpDPheLysNH 2 on growth hormone (GH) releasing factor-stimulated GH release and intracellular adenosine 3' ,5' -monophosphate accumulation in rat primary pituitary cell culture. Endocrinology. 1989; 124:2791-8.
35. Clark RG, Carlsson LMS, Trohnar J, et al. The effects of a growth hormone releasing peptide and growth hormone releasing factor in conscious and anesthetized rats. J Neuroendocrinol. 1989;1:249-55.
36. Smith RG, Pong SS, Hickey G, et al. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Recent Prog Horm Res. 1996;51:261-86.
37. Herrington J, Hille B. Growth hormone-releasing hexapeptide elevates intracellular calcium in rat somatotropes by two mechanisms. Endocrinology. 1994;135:1100-8.
38. Adams EF, Lei T, Buchfelder M, et al. Protein kinase C-dependent growth hormone releasing peptides stimulate cAMP production by human pituitary somatotrophinomas expressing GSP oncogenes: evidence for cross-talk between transduction pathways. Mol Endocrinol. 1996;10:432-8.
39. Mau SE, Witt MR, Bjerrum OJ, et al. Growth hormone releasing hexapeptide (GHRP-6) activates the inositol (1,4,5)-triphosphate/diacylglycerol pathway in rat anterior pituitary cells. J Recept Signal Transduct Res. 1995;15:311-23.
40. Kraicer J, Sims SM. Ionic mechanisms governing the control of growth hormone secretion by somatostatin. In: Bercu B, Walker R, editors. Growth hormone II. New York, NY: Springer Verlag; 1994. p. 17-32.
41. Chihara K, Kaji H, Hayashi S, et al. Growth hormone releasing hexapeptide: basic research and clinical application. In: Bercu B, Walker R, editors. Growth hormone II. New York, NY: Springer Verlag; 1994. p. 223-30.
42. Dickson SL, Leng G, Robinson ICAF. Systemic administration of growth hormone releasing peptide activates hypothalamic arcuate neurons. Neuroscience. 1993;53:303-6.
43. Dickson SL, Luckman SM. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology. 1997;138:771-7.
44. Dickson SL, Leng G, Dyball REJ, et al. Central actions of peptide and non-peptide growth hormone secretagogues in the rat. Neuroendocrinology. 1995;61:36-43.
45. Dickson SL, Doutrelant-Viltart O, Leng G. Growth hormone (GH) de fi cient dw/dw rats and lit/ lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH-releasing peptide (GHRP-6). J Endocrinol. 1995;146:519-26.
46. Kamegai J, Hasegawa O, Minami S, et al. The growth hormone releasing peptide KP-102 induces c-fos expression in the arcuate nucleus. Mol Brain Res. 1996;39:153-9.
47. Chan YY, Steiner RA, Clifton DK. Regulation of hypothalamic neuropeptide-Y neurons by growth hormone in the rat. Endocrinology. 1996;137:1319-25.
48. Howard AD, Scott D, Feighner SD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974-7.
49. Locke W, Kirgis HD, Bowers CY, et al. Effects of intracerebroventricular injection of a growth hormone releasing peptide on feeding behavior and plasma growth hormone levels of rats. Life Sci. 1995;56:1347-52.
50. Okada K, Ishii S, Minami S, et al. Intracerebroventricular administration of the growth hormone releasing peptide KP-102 increases food intake in free-feeding rats. Endocrinology. 1996;137:5155-8.
51. Fairhall KM, Mynett A, Thomas GB, et al. Central and peripheral effects of peptide and nonpeptide GH secretagogues on GH release in vivo. In: Bercu B, Walker R, editors. Growth hormone secretagogues. New York, NY: Springer-Verlag; 1996. p. 219-36.
52. Evans BE, Rittle KE, Bock MG, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 1988;31:2235-46.
53. Bowers CY. GH releasing peptides (GHRPs). In: Kostyo JL, Goodman HM, editors. Handbook of physiology. New York, NY: Oxford University Press; 1999. p. 267-97.
54. Pong SS, Chaung LYP, Dean DC, et al. Identi fi cation of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol. 1996;10:57-61.
55. Smith RG, Van Der Ploeg LHT, Howard AD, et al. Peptodomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18:621-45.
56. Van der Ploeg LHT, Howard AD, Smith RG, et al. Molecular cloning and characterization of human, swine, and rat growth hormone secretagogue receptors. In: Bercu BB, Walker RF, editors. Growth hormone secretagogues. New York, NY: Marcel Dekker, Inc; 1998. p. 57-76.
57. Feighner SD, Howard AD, Prendergast K, et al. Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. Mol Endocrinol. 1998;12:137-45.
58. Gnanapavan B, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87:2988-91.
59. Holst B, Cygankiewicz A, Halkjaer T, et al. High constitutive signaling of the ghrelin receptor: identi fi cation of a potent inverse agonist. Mol Endocrinol. 2003;17:2201-10.
60. Tannenbaum GS, Khoja ZJ, Chang JK, et al. Inhibition of food intake, body weight and GH release via a putative ghrelin O -acyltransferase (GOAT) inhibitor. The Endocrine Society 92nd annual meeting. San Diego, CA. June 19-22, 2010.
61. Holst B, Schwartz TW. Ghrelin receptor mutations-too little height and too much hunger. J Clin Invest. 2006;116:637-41.
62. Bowers CY, Laferrere B, Hurley DL, et al. The role of growth hormone secretagogues and ghrelin in feeding and body composition. In: Donohoue PA, editor. Energy metabolism and obesity. Totowa, NJ: Humana Press, Inc; 2008. p. 125-54.
63. Zigman JM, Jones JE, Lee CE, et al. Expression of ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol. 2006;494:528-48.
64. Petersen PS, Woldbye DPD, Madsen AN, et al. In vivo characterization of high basal signaling from the ghrelin receptor. Endocrinology. 2009;150:4920-30.
65. Korbonits M. Tumours and humors. In: Kleinberg DL, Clemmons DR, editors. Central and peripheral mechanisms in pituitary disease. Bristol: BioScienti fi ca Ltd; 2002. p. 245-62.
66. Tannenbaum GS, Bowers CY. Interaction of growth hormone secretagogues and growth hormone releasing hormone/somatostatin. Endocrine. 2001;14:21-7.
67. Tannenbaum GS, Eplelbaum J, Bowers CY. Interrelationship between the novel peptide ghrelin and somatostatin/GHRH in regulation of pulsatile growth hormone secretion. Endocrinology. 2003;144:967-74.
68. Bowers CY, Reynolds GA, Durham D, et al. Growth hormone releasing peptide stimulates GH release in normal men and acts synergistically with GH releasing hormone. J Clin Endocrinol Metab. 1990;70:975-82.
69. Ilson BE, Jorkasky DK, Curnow RT, et al. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab. 1989;69:212-4.
70. Jaffe CA, Ho PJ, De-Mott-Friberg R, et al. Effects of a prolonged growth hormone (GH) releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab. 1993;77:1641-7.
71. Huhn WC, Hartman ML, Pezzoli SS, et al. Twenty-four hour growth hormone (GH) releasing peptide (GHRP) infusion enhances pulsatile GH secretion and speci fi city attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab. 1993;76:1202-8.
72. Chapman IM, Hartman ML, Pezzoli SS, et al. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone releasing peptide mimetic, L-692,429, in older adults-a clinical research center study. J Clin Endocrinol Metab. 1996;81:2874-80.
73. Pandya N, De-Mott-Friberg R, Bowers CY, et al. Growth hormone (GH) releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83:1186-9.
74. 2), GHRH and TRH in acromegaly. J Clin Endocrinol Metab. 1993;77:842-5.
75. Bowers CY, Granda R, Mohan S, et al. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004;89:2290-300.
76. Bowers CY, GHRP: Unatural toward the natural. In: Ghigo E, Boghen M, Casanueva FF, Dieguez C, editors. Growth hormone secretagogues: basic fi ndings and clinical implications. Amsterdam: Elsevier Science; 1999. p. 5-18.
77. van der Lely AJ, Tschop M, Heiman ML, et al. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004;25:426-57.
78. Veldhuis JD, Roemmich JN, Richmond EJ, et al. Somatotropic and gonadotropic axes linkages in infancy, childhood, and the puberty-adult transition. Endocr Rev. 2006;27:101-40.
79. Korbonits M, Goldstone AP, Gueorguiev M, et al. Ghrelin-the hormone with multiple functions. Front Nueroendocrinol. 2004;25:27-68.
80. Giustina A, Vedhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19:717-97.
81. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-60.
82. Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86:1464-9.
83. Gurd W, Parent G, Eniojukan R, et al. Interrelationship between the novel peptide ghrelin and somatostatin/GHRH in regulation of pulsatile GH secretion. The Endocrine Society 83rd annual meeting. Denver, CO. June 20-23, 2001.
84. Tannenbaum GS, Epelbaum J, Bowers CY. Ghrelin and the growth hormone neuroendocrine axis. In: Kordon C et al., editors. Brain somatic cross-talk and the central control of metabolism. Berlin/Heidelberg: Springer-Verlag; 2002. p. 65-80.
85. Hataya Y, Akamizu T, Takaya K, et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab. 2001;86:4552-5.
86. Veldhuis JD, Reynolds GA, Iranmanesh A, et al. Twenty-four hour continuous ghrelin infusion augments physiological feed-back modes of growth hormones secretion. J Clin Endocrinol Metab. 2008;93:3597-603.
87. Date Y, Murakami N, Toshinai K, et al. The role of the gastric afferent vagal nerve in ghrelininduced feeding and growth hormone secretion in rats. Gastroenterology. 2002;123:1120-8.
88. Veldhuis JD, Bowers CY. Integrating GHS into the ghrelin system. Int J Pept. 2010;Article ID 879503:1-40.
89. Farhy LS, Veldhuis JD. Deterministic construct of amplifying actions of ghrelin on pulsatile GH secretion. Am J Physiol Regul Integr Comp. 2005;288:R1649-63.